Compare International Flavors & Fragrances Inc. Common Stock (IFF) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
International Flavors & Fragrances Inc. Common Stock vs Repligen Corporation Common Stock — how do they compare? International Flavors & Fragrances Inc. Common Stock trades at $89.51 (market cap $22.50B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: International Flavors & Fragrances Inc. Common Stock is far larger — about 2× Repligen Corporation Common Stock's market cap, and International Flavors & Fragrances Inc. Common Stock pays a 1.81% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold International Flavors & Fragrances Inc. Common Stock for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| IFF | RGEN | |
|---|---|---|
Market Cap | $22.50B | $11.14B |
Volume | 3,000,517 | 1,259,263 |
Sector | Basic Materials | Health |
52-Week High | $89.60 | $194.57 |
52-Week Low | $61.49 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $28.18B | $11.02B |
Dividend Yield | 1.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IFF trades at $88.2, up 3.81% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $361 million in 2025 but returned to profitability in 2026 with $277 million net income. Recent news highlights product innovations like AQUASCENT™ and life-stage dairy insights. Analyst consensus is strongly bullish with a $95 price target, though valuation ratios like P/E of 80.92 appear elevated relative to earnings.
The outlook for IFF hinges on sustaining its 2026 profitability turnaround and executing growth initiatives. Investment opportunities include market leadership in flavors and fragrances and new technology launches. Key risks are high debt levels, competitive pressures, and sensitivity to consumer spending trends. The stock's upside is supported by analyst optimism but requires careful monitoring of earnings consistency.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About International Flavors & Fragrances Inc. Common Stock
International Flavors & Fragrances develops ingredients and solutions used in food, beverages, personal care, home care, health, and biosciences applications. Its portfolio includes flavors, fragrances, cultures, enzymes, and nutrition ingredients.
Read more on IFF →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
